Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax (Euronext Paris: ABVX), a clinical-stage biotechnology company, announced the resumption of trading for its ordinary shares on Euronext Paris effective July 24, 2025, at 3:30 p.m. CEST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Abivax (Euronext Paris: ABVX), a clinical-stage biotechnology company, announced the resumption of trading for its ordinary shares on Euronext Paris effective July 24, 2025, at 3:30 p.m. CEST.
The trading halt, which began at 9:00 a.m. CEST on the same day, was implemented to facilitate the allocation process and pricing announcement of the company's American Depositary Shares (ADS) offering in the United States. Each ADS represents one ordinary share with a nominal value of €0.01.
Positive
- None.
Negative
- Potential dilution for existing shareholders through ADS offering
Details
News Market Reaction – ABVX
The recorded move for ABVX in the trading session of this news was +1.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Abivax announces trading resumption of its ordinary shares on Euronext Paris
PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. CEST.
Trading of the ordinary shares of the Company was halted at the request of the Company on July 24, 2025 from 9:00 a.m. CEST in the context of the previously announced public offering by the Company of its American Depositary Shares, each representing one ordinary share,
***
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Contacts:
| Abivax Investor Relations Patrick Malloy patrick.malloy@abivax.com +1 847 987 4878 |
***
Disclaimer
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.